Progenics Pharmaceuticals Inc

Progenics Pharmaceuticals — Investor Presentation (January 2019)

28 slides from Progenics Pharmaceuticals's investor presentation, Jan 4, 2019

  1. Slide 1: Leading Development of Radiopharmaceuticals to Detect and Treat Cancer

    Leading Development of Radiopharmaceuticals to Detect and Treat Cancer January 2019 ~ Progenics Find Fight and Follow"

  2. Slide 2: Disclosure notice

    Disclosure notice This presentation may contain projections and other forward-looking statements regarding future events. Such statements are predictions only, and are subjectto risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties incl

  3. Slide 3: Prostate-specific membrane antigen (PSMA)

    Prostate-specific membrane antigen (PSMA) Ultra Orphan neuroendocrine tumors (NE rtfolio for Prostate Cance' First FDA-approvedtreatment for adults and pediatric patients 12 years and older with iobenguane scan positive, unresectable, Imaging and therapeutics locally advanced or metastatic agents de

  4. Slide 4: Pipeline

    Pipeline Preclinical Phase1 Phase2 Phase 3 NDA Approved ULTRA-ORPHAN THERANOSTIC AZEDRA® APPROVED & Paraganglioma OSTATE CANCER THERANOSTICS PyL™ T Imaging Agent PSMA-targeted Small Mo Therap PSMA-TTC Thorium Conjugate Therapeutic DIGITAL TECHNOLOGY PSMA Al 9 of OIC TREATMENT. RELISTOR® SC induced C

  5. Slide 5: FDA Approved: AZEDRA

    FDA Approved July 30, 2018 MAY Waa. SY WA yf WL. AZEDRA® (iobenguane | 131) First and only FDA-approved treatment for adults and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic an

  6. Slide 6: PPGL are very rare diseases with devastating patient burden

    Pheochromocytoma and paraganglioma (PPGL) are very rare diseases with devastating patient burden eeege5e50585%007 S089 Seeesseseebos ay 652-1 2,608 patients diagnosed each year in the US"? ges oe If PPGL tumors are not diagnosed and appropriately treated, the disease will likely be fatal? The 5-year

  7. Slide 7: Historically underappreciated, consensus now indicates all PPGL at risk

    Historically underappreciated, consensus now indicates that all cases of PPGL should be considered at-risk for advanced disease Average time from onset of World Health Organization symptoms to diagnosis is 3 years" states all PPGL tumors have ‘i Ate 1 5% of cases are advanced cost mtese pane re at d

  8. Slide 8: The leading causes of death in advanced PPGL

    The leading causes of death in advanced PPGL are tumor progression and symptoms related to catecholamine secretion Control tumor growth Reduce symptoms Tumor progression is the most Symptoms related to catecholamine frequent cause of death.’ secretion such as hypertension cause up to 30% of metastat

  9. Slide 9: AZEDRA

    AZEDRA References: BarettJA, tal. Cancer Bother Radiophar. 2010;25(9}299-308, AZEDRA prescrbing formation, New York, NY:Progenios ibenguae 13

  10. Slide 10: AZEDRA addresses the dual goals of treating advanced PPGL

    yw AZEDRA addresses the dual goals of treating advanced PPGL: tumor reduction and symptom contro! AZEDRA was proven to reduce the need for antihypertensive medication AZEDRA was shown to reduce the size of tumors Secondary Endpoint Primary Endpoint Overall tumor response measured Proportion of patie

  11. Slide 11: AZEDRA Safety Profile

    AZEDRA Safety Profile Adverse Reactions Occurring in 210% of Patients with PPGL Receiving Therapeutic Dose of AZEDRA in Studies IB12B and IB12 evens % Eres » os * tnsenes tied oane pete Ante aeoneneesarc a Increased aspartate aminotransterase, hereto co bah Increased alanine aminctransterave Seeman

  12. Slide 12: AZEDRA launch is underway with progress in key commercial areas

    Wi AZEDRA launch is underway with progress in key commercial areas Commercial launch — key activities Q Q g Q eed ad Establish meaningful en Patients identified - value proposition E and scheduling compelling and engage payers and Pe parauos has started product profile on-going — NCCN Guidelines — 4

  13. Slide 13: AZEDRA Summary

    AZEDRA Summary PROVEN: AZEDRA® was proven to reduce the need for antihypertensive medication and was shown to reduce the size of tumors GENERALLY WELL TOLERATED: The most common Grade 3—4 adverse reactions (= 10%) were lymphopenia, neutropenia, thrombocytopenia, fatigue, anemia, increased internatio

  14. Slide 14: PSMA Targeted Pipeline

    PSMA Targeted Pipeline Progenics Find Fight and Follow*

  15. Slide 15: PSMA-targeted imaging and therapy has potential across the course of prostate cancer

    PSMA-targeted imaging and therapy has potential across the course of prostate cancer PyL expected usage Post Chemo Surgery or RT+/-ADT| PSMATTC expected usage PSA increase 1095 expected usage Localized Recurrent/ prostate castrate-sensitive cancer disease Castrate-resistant disease Time Progenics, 1

  16. Slide 16: 1095: PSMA targeted small molecule theranostic for prostate cancer

    1095: PSMA targeted small molecule theranostic for prostate cancer .) — 1095 delivers a targeted radiation dose to prostate cancer utilizing 1-131 + 1-131 has a longer range and higher energy that could potentially improve efficacy for bulky lesions + lodine has been used widely in other cancer ther

  17. Slide 17: 1095 was shown to markedly reduce PSA levels and bone pain

    Ne Pg he > 1095 was shown to markedly reduce prostate-specific antigen levels and bone pain ‘German compassionate use setting in Best PSA Responsein 25 patients Sores calniars cress orca « 100 ry 2 £ ra e ° LTT 5 2 oO x 100 "0 5 10 18 20 25 Patient number 7 0 % of patients had a 2 50% PSA decline af

  18. Slide 18: 1095: Multicenter Phase 2 trial expect to initiate 2Q2019

    1095: Multicenter Phase 2 trial expect to initiate 2Q2019 Objective: To determine the efficacy and safety of adjunct |-131-1095 radiotherapy to enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients who are prostate-specific membrane antigen (PSMA)-avid, chemotherapy-naive,

  19. Slide 19: PSMA-Targeted Thorium Conjugate (PSMA-TTC) partnered with Bayer

    PSMA-Targeted Thorium Conjugate (PSMA-TTC) partnered with Bayer — In a prostate cancer mouse model, PSMA-TTC proved efficacious to suppress tumor growth and RK bone degradation’ BAYER R — Phase 1 in patients with mCRPC commenced in 2018 — Potential added effect on bone metastases due to decay produc

  20. Slide 20: PyL: PSMA-targeted PET/CT imaging agent

    PyL™: PSMA-targeted PET/CT imaging agent “ PSMA imaging study found a high impact on management intent, with a planned management change in 51% of patients.” Roach, PJ. et al, JNM 2017 — Enables visualization of both bone and soft tissue metastases — Highly specific to prostate cancer cells, not con

  21. Slide 21: PyL OSPREY trial results support advancement into Phase 3

    PyL OSPREY trial results support advancement into Phase 3 — Demonstrated high sensitivity in detecting distant metastatic prostate cancer lesions — Demonstrated high specificity in confirming the absence of pelvic lymph node disease — Associated strong positive predictive values (PPV) and negative p

  22. Slide 22: PyL Phase 3 trial

    PyL Phase 3 trial Objective: To evaluate the diagnostic performance & clinical impact of 18F_DCFPyL PET/CT imaging in patients with suspected biochemical recurrence (BCR) of prostate cancer ~15 sites in the US and Canada | Total planned subjects: N~200 Primary Endpoint: Correct Localization Rate (CL

  23. Slide 23: Curium exclusive license to commercialize PyL in Europe

    SS e/ Curium can leverage its dense network of PET sites to © reach a significant majority of PCA patients in Europe LIFE FORWARD CUrIUMW — Granted exclusive license to Curium to develop and commercialize PyL in Europe — Formed by the union of IBA Molecular and Mallinckrodt Nuclear Medicine LLC, Cur

  24. Slide 24: Digital Technology Portfolio: PSMA Artificial Intelligence (AI)

    Digital Technology Portfolio: PSMA Artificial Intelligence (Al) — Using expertise from aBS! — a validated imaging biomarker — to develop PSMA computer-aided diagnosis (CAD) — Automated reading of PSMA-targeted images based on deep learning — Using PSMA-targeted imaging data to develop and validate P

  25. Slide 25: Corporate Overview

    Corporate Overview Progenics Find Fight and Follow*

  26. Slide 26: Financial Overview

    Financial Overview 3Q18 Financial Snapshot — $148.9M cash as of 9/30/18 — Quarterly Revenue: $5.3M — Net loss: $0.30 per share — 84.5M shares outstanding Strong financial position to advance portfolio and launch AZEDRA RELISTOR® franchise provides financial foundation: Marketed by Bausch Health Roya

  27. Slide 27: Upcoming milestones

    Leading development of targeted radiopharmaceuticals to detect and treat cancer Upcoming milestones Y Jerasitl se) — Progress Launch — Advance Life Cycle Management Initiatives Initiate Phase 2 Trial — Curium to meet with EMA to determine regulatory path in Europe — Complete Enrollment in Pivotal Ph

  28. Slide 28: Leading Development of Radiopharmaceuticals to Detect and Treat Cancer

    Leading Development of Radiopharmaceuticals to Detect and Treat Cancer January 2019 ~ Progenics Find Fight and Follow"

Progenics Pharmaceuticals — Investor Presentation (January 2019) on 6ix